Reality injection

Joseph Papa says some of the troubled $8 bln drug firm’s businesses are doing fine. But weak earnings and yet another downgrade sent the stock plunging on Tuesday. At under 10 pct of its peak value last year, the new boss will be trying to persuade investors the only way is up.